The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials

Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder

(2012) Christopher R. Chapple et al.   EUROPEAN UROLOGY

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

(2012) Vik Khullar et al.   EUROPEAN UROLOGY

Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder

(2012) Victor W. Nitti et al.   JOURNAL OF UROLOGY

β−Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder

(2010) Brian J. Limberg et al.   CELL AND TISSUE RESEARCH

Low persistence of anticholinergic drug use in Sweden

(2010) Love Linnér et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Patient-reported reasons for discontinuing overactive bladder medication

(2009) Joshua S. Benner et al.   BJU INTERNATIONAL

Expression and functional role of β-adrenoceptors in the human urinary bladder urothelium

(2008) Atsushi Otsuka et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY